Tumor Protein TPT1P6 as a Drug Target and Biomarker (G643870)

Target Name: TPT1P6

NCBI ID: G643870

TPT1P6

Other Name(s): Tumor protein, translationally-controlled 1 pseudogene 6 | TPT1 pseudogene 6

Tumor Protein TPT1P6 as a Drug Target and Biomarker

Tumor suppressors are a promising strategy in cancer treatment, as they can inhibit tumor growth and promote the regression of tumors. Tumor proteins are known to play a crucial role in cancer progression, and targeting them can be an effective way to combat the disease. In this article, we will explore TPT1P6, a tumor protein that is translationally-controlled and has been identified as a potential drug target in cancer.

Tumor Protein TPT1P6

Tumor protein TPT1P6 is a 14 kDa protein that is expressed in various tissues, including human tissues, tissues, and cancer cells. It is localized to the cytoplasm and can be expressed in high levels in some types of cancer, such as breast, ovarian, and colorectal cancer. TPT1P6 has been shown to play a role in cell signaling pathways, including the TGF-β pathway, which is a well-established mechanism of cancer progression.

Expression of TPT1P6

TPT1P6 is translated from a unique start codon, which is located at position 6 on the human chromosome. This is why it is referred to as TPT1P6. The translation of TPT1P6 is highly regulated, and it is expressed in a highly variable manner depending on the cell type and the environmental conditions. In cancer cells, TPT1P6 is often overexpressed, which can lead to its acquisition into a gain-of-function state and contribute to tumor progression.

Drug Targeting TPT1P6

Drug targeting TPT1P6 as a potential therapeutic target is an attractive approach due to its potential impact on cancer progression. Several studies have shown that inhibiting TPT1P6 can lead to a reduction in cancer cell proliferation and the inhibition of cell migration. In addition, TPT1P6 has been shown to play a role in the development of resistance to chemotherapy in cancer cells, which can further enhance its potential as a therapeutic target.

Biomarker TPT1P6

TPT1P6 has also been identified as a potential biomarker for cancer diagnosis and monitoring. The high expression of TPT1P6 in cancer cells makes it a promising target for diagnostic agents that can specifically bind to it. In addition, the regulation of TPT1P6 expression has been shown to be associated with the development of certain types of cancer, such as cancer of the breast and ovarian tissue. Therefore, the expression of TPT1P6 can be used as a biomarker for cancer diagnosis and monitoring in these types of cancer.

Conclusion

Tumor protein TPT1P6 is a promising target for cancer treatment due to its role in cell signaling pathways and its potential as a drug target. The regulation of TPT1P6 expression has been shown to be associated with the development of certain types of cancer, and its inhibition has been shown to lead to a reduction in cancer cell proliferation and the inhibition of cell migration. In addition, TPT1P6 has also been identified as a potential biomarker for cancer diagnosis and monitoring. Further research is needed to fully understand the role of TPT1P6 as a therapeutic target and its potential as a biomarker for cancer.

Protein Name: TPT1 Pseudogene 6

The "TPT1P6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TPT1P6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets